Aegerion Pharmaceuticals Inc. thinks its data will support broad use of Juxtapid lomitapide to treat homozygous familial hypercholesterolemia, despite the availability of a product from Genzyme Corp. that will cost substantially less.

On the other side, Sanofi's Genzyme unit maintains Kynamro mipomersen should be attractive to patients because of fewer labeling restrictions on diet, pregnancy and concomitant medications.